JP2016534092A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016534092A5 JP2016534092A5 JP2016529755A JP2016529755A JP2016534092A5 JP 2016534092 A5 JP2016534092 A5 JP 2016534092A5 JP 2016529755 A JP2016529755 A JP 2016529755A JP 2016529755 A JP2016529755 A JP 2016529755A JP 2016534092 A5 JP2016534092 A5 JP 2016534092A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antibody
- antigen
- cl2a
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/948,732 | 2013-07-23 | ||
| US13/948,732 US9028833B2 (en) | 2012-12-13 | 2013-07-23 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity |
| PCT/US2014/034518 WO2015012904A2 (en) | 2012-12-13 | 2014-04-17 | Antibody-sn-38 immunoconjugates with a cl2a linker |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016534092A JP2016534092A (ja) | 2016-11-04 |
| JP2016534092A5 true JP2016534092A5 (https=) | 2017-04-27 |
| JP6427789B2 JP6427789B2 (ja) | 2018-11-28 |
Family
ID=54873835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016529755A Active JP6427789B2 (ja) | 2013-07-23 | 2014-04-17 | Ｃｌ２ａリンカーを有する抗体−ｓｎ−３８免疫複合体 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3024460B1 (https=) |
| JP (1) | JP6427789B2 (https=) |
| CN (2) | CN110075295A (https=) |
| AU (1) | AU2014293670B2 (https=) |
| CA (1) | CA2914438C (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10639378B2 (en) * | 2016-06-06 | 2020-05-05 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
| CN109562172B (zh) * | 2016-08-11 | 2022-08-16 | 免疫医疗公司 | 抗HLA-DR抗体药物缀合物IMMU-140(hL243-CL2A-SN-38)在HLA-DR阳性癌症中的功效 |
| CN108066772B (zh) * | 2016-11-14 | 2021-07-13 | 中国科学院上海药物研究所 | 靶向tacstd2的抗体与药物偶联体(adc)分子 |
| CN110248680A (zh) * | 2016-12-01 | 2019-09-17 | 免疫医疗公司 | 使用抗体-药物缀合物沙西妥珠单抗戈维替康(immu-132)的用于转移性尿路上皮癌的疗法 |
| JP7204132B2 (ja) * | 2017-05-02 | 2023-01-16 | 国立研究開発法人国立がん研究センター | プラスミンにより切断可能な抗不溶性フィブリン抗体と薬物とのコンジュゲート |
| EP3725798B1 (en) * | 2017-12-15 | 2026-03-04 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Bioactive conjugate, preparation method therefor and use thereof |
| CN111542324B (zh) * | 2018-02-11 | 2023-09-12 | 四川科伦博泰生物医药股份有限公司 | 细胞毒性剂及其偶联物、其制备方法及用途 |
| CA3096222A1 (en) | 2018-04-06 | 2019-10-10 | Atyr Pharma, Inc. | Compositions and methods comprising anti-nrp2 antibodies |
| EP3826673A4 (en) * | 2018-07-26 | 2022-03-09 | Tayu Huaxia Biotech Medical Group Co., Ltd. | COMPOSITIONS AND METHODS FOR IMAGING |
| CN113454108B (zh) * | 2019-01-23 | 2025-02-14 | 米伦纽姆医药公司 | 包含去免疫化志贺菌毒素a亚基效应子的cd38结合蛋白 |
| CN114746120B (zh) | 2019-10-03 | 2024-07-30 | Atyr医药公司 | 包含抗nrp2抗体的组合物和方法 |
| AU2020410460A1 (en) * | 2019-12-16 | 2022-06-16 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-CEA antibody-exatecan analog conjugate and pharmaceutical use thereof |
| MX2022008474A (es) | 2020-01-22 | 2022-08-02 | Jiangsu Hengrui Medicine Co | Conjugado de anticuerpo anti-trop-2-analogo de exatecan y uso medico del mismo. |
| CN111499685A (zh) * | 2020-03-30 | 2020-08-07 | 联宁（苏州）生物制药有限公司 | 具有马来酰亚胺连接头的抗体偶联药物中间体及其合成方法 |
| CN113527496B (zh) * | 2020-04-16 | 2022-03-04 | 上海洛启生物医药技术有限公司 | 抗Trop2纳米抗体及其应用 |
| KR102349925B1 (ko) * | 2020-07-16 | 2022-01-12 | 주식회사 피노바이오 | Fl118 약물을 포함하는 화합물 및 이를 이용한 면역접합체 |
| CN116472064A (zh) * | 2020-10-12 | 2023-07-21 | 昆山新蕴达生物科技有限公司 | 抗体-药物偶联物及其应用 |
| CN117015545A (zh) * | 2021-03-12 | 2023-11-07 | 国立研究开发法人科学技术振兴机构 | Sn-38衍生物、包含该衍生物的纳米粒子、医药及该纳米粒子的制造方法 |
| CN113480651B (zh) * | 2021-07-19 | 2022-07-08 | 华东师范大学 | 一种靶向人cd133的纳米抗体及其制备方法和应用 |
| MX2024000895A (es) | 2021-07-21 | 2024-02-06 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Composicion farmaceutica que contiene el conjugado del farmaco anticuerpo anti-trop2 y su aplicacion. |
| CA3246696A1 (en) * | 2022-04-14 | 2025-02-03 | Suzhou Ribo Life Science Co., Ltd. | CONJUGATES AND COMPOSITION, AS WELL AS THEIR PREPARATION PROCESS AND USE |
| CN114917222B (zh) * | 2022-04-29 | 2023-02-28 | 佛山病原微生物研究院 | 一种Ganetespib在制备用于抗腺病毒感染的药物中的用途 |
| CN116139267A (zh) * | 2023-01-28 | 2023-05-23 | 华中科技大学同济医学院附属同济医院 | 小鼠cd74单克隆抗体在制备治疗肿瘤药物中的应用 |
| CN119775347B (zh) * | 2024-12-31 | 2025-10-10 | 英科新创（苏州）生物科技有限公司 | 水溶性吖啶磺酰胺羧酸标记物、制备方法、其应用及试剂盒 |
| CN119775344B (zh) * | 2024-12-31 | 2025-08-26 | 英科新创（苏州）生物科技有限公司 | 水溶性吖啶磺酰胺衍生物、制备方法、其应用及试剂盒 |
| CN121177511A (zh) * | 2025-11-05 | 2025-12-23 | 赣南医科大学 | Immu-132与gsk2606414联用在制备抗结直肠癌药物中的应用及相关药物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0028361D0 (en) * | 2000-11-21 | 2001-01-03 | Glaxo Group Ltd | Method of separating extra chromosomal dna from other cellular components |
| SE0104462D0 (sv) * | 2001-12-29 | 2001-12-29 | Carlbiotech Ltd As | Peptide purifcation (Peptidrening) |
| US8420086B2 (en) * | 2002-12-13 | 2013-04-16 | Immunomedics, Inc. | Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases |
| EP3912643B8 (en) * | 2009-02-13 | 2023-08-23 | Immunomedics, Inc. | Immunoconjugates with an intracellularly-cleavable linkage |
| US9198972B2 (en) * | 2010-01-28 | 2015-12-01 | Alnylam Pharmaceuticals, Inc. | Monomers and oligonucleotides comprising cycloaddition adduct(s) |
| SI2900277T1 (sl) * | 2012-12-13 | 2022-05-31 | Immunomedics, Inc. | Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost |
-
2014
- 2014-04-17 AU AU2014293670A patent/AU2014293670B2/en active Active
- 2014-04-17 EP EP14828674.3A patent/EP3024460B1/en active Active
- 2014-04-17 CA CA2914438A patent/CA2914438C/en active Active
- 2014-04-17 CN CN201910347750.9A patent/CN110075295A/zh active Pending
- 2014-04-17 CN CN201480041766.2A patent/CN105407891A/zh active Pending
- 2014-04-17 JP JP2016529755A patent/JP6427789B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016534092A5 (https=) | ||
| JP2016520548A5 (https=) | ||
| JP2012500286A5 (https=) | ||
| JP2016513098A5 (https=) | ||
| US10758625B2 (en) | Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof | |
| JP7238030B2 (ja) | Ｔ細胞療法のために患者をコンディショニングする方法 | |
| KR102481922B1 (ko) | T 세포 요법을 위한 진단 방법 | |
| CN107735090B (zh) | 具有cl2a接头的抗体-sn-38免疫缀合物 | |
| JP2013503184A5 (https=) | ||
| US10669338B2 (en) | Anti-PD-1 checkpoint inhibitor antibodies that block binding of PD-L1 to PD-1 | |
| FI3903829T3 (fi) | Solunsisäisesti katkeavan sidoksen omaavia immunokonjugaatteja | |
| JPWO2020021045A5 (https=) | ||
| US9657093B2 (en) | Methods for treating sepsis using chimeric and humanized anti-histone antibodies | |
| US20240252537A1 (en) | Precision molecular adaptor system for car-t immunotherapy | |
| JP2021185187A (ja) | 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する | |
| JP2014514345A5 (https=) | ||
| WO2016172427A1 (en) | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells | |
| US10206918B2 (en) | Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers | |
| JP2016534092A (ja) | Ｃｌ２ａリンカーを有する抗体−ｓｎ−３８免疫複合体 | |
| US20170216447A1 (en) | Combination therapy with anti-hla-dr antibodies and kinase inhibitors in hematopoietic cancers | |
| EP3496754A1 (en) | EFFICACY OF ANTI-HLA-DR ANTIBODY DRUG CONJUGATE IMMU-140 (hL243-CL2A-SN-38) IN HLA-DR POSITIVE CANCERS | |
| Wang et al. | Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-Hodgkin lymphoma | |
| WO2021022044A1 (en) | Depletion regimes for engineered t-cell or nk-cell therapy | |
| Xu et al. | Targeting diverse chimeric antigen receptor T cell-related targets in treatment of B-cell hematological malignancies: a review of long-term follow-up data | |
| CN119638851A (zh) | 一种用于桥接造血干细胞移植的多靶点嵌合抗原受体及其应用 |